Skip to main content

Market Overview

BriaCell Stock Is Trading Higher After Encouraging Bria-IMT Data At AACR Annual Meeting

Share:
BriaCell Stock Is Trading Higher After Encouraging Bria-IMT Data At AACR Annual Meeting
  • BriaCell Therapeutics Corp (NASDAQ: BCTX) has announced the presentation of results from clinical studies evaluating its lead product candidate, Bria-IMT, at the American Association for Cancer Research (AACR) Annual Meeting 2021.
  • The findings indicate disease control in advanced breast cancer patients, including stable disease (SD), partial responses (PR), or complete responses (CR).
  • The Bria-IMT regimen with or without checkpoint inhibitors can induce an effective immune response and disease control in heavily pre-treated advanced breast cancer patients.
  • Delayed-Type Hypersensitivity (DTH) to Bria-IMT analysis identified a group with significantly higher rates of disease control and progression-free survival (8 months) in both monotherapy and combination therapy studies suggesting a robust immune response is predictive of clinical benefit in these patients.
  • The highest levels of disease control and progression-free survival were observed in patients who matched Bria-IMT at 2 or more HLA alleles in the monotherapy study but not in the combination therapy with Bria-OTS, off-the-shelf personalized immunotherapy for advanced breast cancer.
  • Patients with Grade I/II tumors (median of 8 prior therapy regimens) were more likely to respond with the disease control (67%) and longer progression-free survival.
  • The response was evident in the patients in the combination therapy study suggesting synergistic effects of checkpoint inhibitors combined with the Bria-IMT regimen.
  • BriaCell is currently conducting a Phase 1/2a clinical trial of Bria-IMT in a Combination Study with immune checkpoint inhibitors.
  • Price Action: BCTX shares are up 2.1% at $5.32 during the premarket session on the last check Monday.
 

Related Articles (BCTX)

View Comments and Join the Discussion!

Posted-In: Briefs cancer Phase 2 TrialBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com